Brain natriuretic peptide is associated with survival in persons with dysvascular major lower limb amputation
Main Article Content
Abstract
Brain natriuretic peptide (pg/ml) is a cardioprotective hormone released in response to pressure or volume overload of the heart. High preoperative brain natriuretic peptide levels in persons with dysvascular major lower limb amputation may indicate cardiac stress threatening survival. The aim of this retrospective database study was to analyze the association between brain natriuretic peptide, heart failure and survival in persons with dysvascular major lower limb amputation.
Data of persons with dysvascular major lower limb amputations, at Nij Smellinghe Hospital (2010 to 2018), were included. Brain natriuretic peptide levels, determined pre- and/or post-amputation, were collected. Persons were categorized in two groups: ‘low’ brain natriuretic peptide (≤91 pg/ml) and ‘high’ brain natriuretic peptide (>91 pg/ml).
Data of 59 persons (median ge 73, interquartile range 66;80, 42 males) were included. Survivors had a significantly lower preoperative brain natriuretic peptide level (median 46, interquartile range 21;75) compared to non-survivors (median 135, interquartile range 38;316, Mann-Whitney U Test: p=0.029) and postoperative brain natriuretic peptide levels (median 26, interquartile range 16;42) compared to non-survivors (median 176, interquartile range 61;323, p=0.007). The ‘low’ brain natriuretic peptide group lived significantly longer (median 2305 days, interquartile range 1361;2979) than the ‘high’ brain natriuretic peptide group (median 687 days, interquartile range 87;1224, Log Rank=20.843; Kaplan-Meier: p=<0.001). Persons with high brain natriuretic peptide and heart failure lived shorter than those with low brain natriuretic peptide and heart failure (Kruskal-Wallis Test: p=0.008) and those with low brain natriuretic peptide without heart failure (p=0.004). Survival was shortest in the group with the high brain natriuretic peptide levels and heart failure.
In this small study, brain natriuretic peptide levels, also combined with heart failure, were associated with survival in persons with a major lower limb amputation.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Cruz CP, Eidt JF, Capps C, Kirtley L, Moursi MM. Major lower extremity amputations at a Veterans Affairs hospital. Am J Surg. 2003;186(5):449-454. doi: 10.1016/j.amjsurg.2003.07.027.
3. Stern JR, Wong CK, Yerovinkina M, et al. A meta-analysis of long-term mortality and associated risk factors following lower extremity amputation. Ann Vasc Surg. 2017;42:322-327. doi:10.1016/j.avsg. 2016.12.015.
4. Morton C, Rolle N, Sahoo S, Kaufman M, Drucker C, Nagarsheth K. Predictive factors for mortality following major lower extremity amputation. Am Surg. 2023;89(12):5669-5677. doi:10.1177/000313 48231167396.
5. Thorud JC, Plemmons B, Buckley CJ, Shibuya N, Jupiter DC. Mortality after nontraumatic major amputation among patients with diabetes and peripheral vascular disease: a systematic review. J Foot Ankle Surg. 2016;55(3):591-599. doi:10.1053 /j.jfas.2016.01.012.
6. Aulivola B, Hile CN, Hamdan AD, et al. Major lower extremity amputation—outcome of a modern series. Arch Surg. 2004;139:395-399. doi:10.1001/archsurg.139.4.395.
7. Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2022;27(2):625-643. doi:10.1007/s10741-021-10105-w.
8. Stone PA, Thompson SN, Williams D, et al. Biochemical markers in patients with open reconstructions with peripheral arterial disease. Vascular. 2016;24(5):461-468. doi:10.1177/170853 8115611302.
9. Yannoutsos A, Lin F, Gaisset R, et al. Characteristics and outcomes of octogenarians with revascularized critical limb ischemia: impact of altered cardiac function for early mortality. J Med Vasc. 2021;46(5-6):224-231. doi:10.1016/j.jdmv. 2021.10.003.
10. Starholm IM, Mirtaheri P, Kapetanovic N, et al. Energy expenditure of transfemoral amputees during floor and treadmill walking with different speeds. Prosthet Orthot Int. 2016;40(3):336-342. doi:10.1177/0309364615588344.
11. Vllasolli TO, Zafirova B, Orovcanec N, Poposka A, Murtezani A, Krasniqi B. Energy expenditure and walking speed in lower limb amputees: a cross-sectional study. Ortop Traumatol Rehabil. 2014;16 (4):419-426. doi:10.5604/15093492.1119619.
12. Moore TJ, Barron J, Hutchinson F 3rd, Golden C, Ellis C, Humphries D. Prosthetic usage following major lower extremity amputation. Clin Orthop Relat Res. 1989;(238):219-224.
13. Kaptein S, Geertzen JHB, Dijkstra PU. Association between cardiovascular diseases and mobility in persons with lower limb amputation: a systematic review. Disabil Rehabil. 2018;40(8):883-888. doi: 10.1080/09638288.2016.1277401.
14. Chin T, Sawamura S, Fujita H, et al. Physical fitness of lower limb amputees. Am J Phys Med Rehabil. 2002;81(5):321-5. doi: 10.1097/00002060 -200205000-00001.
15. Simmelink EK, Dijkstra PU, de Bruijn MC, et al. Interobserver and intraobserver reliabilities of determining the ventilatory thresholds in subjects with a lower limb amputation and able-bodied subjects during a peak exercise test on the combined arm-leg (Cruiser) ergometer. Int J Rehabil Res. 2022;45(3):243-252. doi: 10.1097/ MRR.0000000000000536.
16. Riemersma M, Dijkstra PU, van Veldhuisen DJ, Muskiet FA, van den Dungen JA, Geertzen JHB. Mortality and preoperative cardiac function in vascular amputees: an N-terminal pro-brain natriuretic peptide (NT-proBNP) pilot study. Clin Rehabil. 2008;22:56-59. doi:10.1177/0269215507079864.
17. Hill SA, Booth RA, Santaguida PL, et al. Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence. Heart Fail Rev. 2014;19 (4):421-438. doi:10.1007/s10741-014-9447-6.
18. Maries L, Manitiu I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovasc J Afr. 2013;24(7):286-289. doi:10.5830/CVJA-2013-055.
19. Rutten JH, Boomsma F, Van den Meiracker AH. Diagnostische en prognostische waarde van B-type-natriuretische peptiden bij hartfalen of bij aanwijzingen daarvoor [Diagnostic and prognostic value of B-type natriuretic peptides in heart failure or signs of heart failure]. Ned Tijdschr Geneeskd. 2007;151(46):2553-2557.
20. Berry C, Kingsmore D, Gibson S, et al. Predictive value of plasma brain natriuretic peptide for cardiac outcome after vascular surgery. Heart. 2006;92(3):401-2. doi: 10.1136/hrt.2005.060988.
21. Bhalla V, Willis S, Maisel AS. B-type natriuretic peptide: the level and the drug—partners in the diagnosis of congestive heart failure. Congest Heart Fail. 2004;10(1 Suppl 1):3-27. doi:10.1111 /j.1527-5299.2004.03310.x.
22. Lim JY, Jung SH, Choo SJ, Chung CH, Lee JW, Kim JB. B-type natriuretic peptide as a surrogate marker for survival in patients undergoing cardiac surgery. J Thorac Dis. 2021;13(2):955-967. doi: 10.21037/jtd-20-2375.
23. Wayne Causey M, Singh N. Clinical implications of B-type natriuretic peptide and N-terminal pro--B-type natriuretic peptide in the care of the vascular surgery patient. Semin Vasc Surg. 2014;27(3-4):143-147. doi: 10.1053/j.semvascsurg. 2015.01.004.
24. Zhang C, Huang D, Shen D, et al. Brain Natriuretic Peptide as the long-term cause of mortality in patients with cardiovascular disease: a retrospective cohort study. Int J Clin Exp Med. 2015;8(9):16364-8.
25. Karthikeyan G, Moncur RA, Levine O, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol. 2009;54(17):1599-1606. doi: 10.1016/j.jacc.2009.06.028.
26. Singh A, Kumar A, Hai AA, Masihullah M, Tripathy N, Singh PK. Serum B-type natriuretic peptide levels (BNP) can be used as a predictor of complications in patients undergoing non-cardiac surgery: a prospective observational study. Open Heart. 2023;10(1):e002256. doi: 10.1136/openhrt-2023-002256.
27. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351(9095):9-13. doi: 10.1016/s0140-6736(97)03034-1.
28. Ettema S, Kal E, Houdijk H. General estimates of the energy cost of walking in people with different levels and causes of lower-limb amputation: a systematic review and meta-analysis. Prosthet Orthot Int. 2021;45(5):417-427. doi:10.10 97/PXR.0000000000000035.
29. Cardarelli R, Lumicao TG. B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians. J Am Board Fam Pract. 2003;16:327-333. doi:10.3122/jabfm.16.4.327.
30. Bruins S, Fokkema MR, Römer JW, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem. 2004;50(11):2052-8. doi: 10.1373/clinchem. 2004.038752.
31. Fard B, Dijkstra PU; NEDA Study Group; Voesten HGJM, Geertzen JHB. Mortality, reamputation, and preoperative comorbidities in patients undergoing dysvascular lower limb amputation. Ann Vasc Surg. 2020;64:228-238. doi: 10.1016/j.avsg.2019.09.010.
32. Jones WS, Patel MR, Dai D, et al. High mortality risks after major lower extremity amputation in Medicare patients with peripheral artery disease. Am Heart J. 2013;165(5):809-815. doi:10.1016/j.ahj.2012.12.002.
33. Fortington LV, Geertzen JH, van Netten JJ, Postema K, Rommers GM, Dijkstra PU. Short and long term mortality rates after a lower limb amputation. Eur J Vasc Endovasc Surg. 2013;46(1): 124-131. doi: 10.1016/j.ejvs.2013.03.024.
34. Subramaniam B, Pomposelli F, Talmor D, Park KW. Perioperative and long-term morbidity and mortality after above-knee and below-knee amputations in diabetics and nondiabetics. Anesth Analg. 2005;100(5):1241-1247. doi: 10.1213/01. ANE.0000147705.94738.31.
35. Wang Y, Zhang R, Huang Y, et al. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients. Clin Chim Acta. 2019 Apr;491:8-14. doi: 10.1016/ j.cca.2018.12.025.